Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Change in Accured Expenses (2016 - 2025)

Haemonetics (HAE) has 17 years of Change in Accured Expenses data on record, last reported at -$6.7 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 302.36% year-over-year to -$6.7 million; the TTM value through Dec 2025 reached -$19.3 million, down 251.75%, while the annual FY2025 figure was -$19.2 million, 143.08% down from the prior year.
  • Change in Accured Expenses reached -$6.7 million in Q4 2025 per HAE's latest filing, down from $17.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $49.5 million in Q1 2024 and bottomed at -$47.9 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $51750.0, with a median of $3.9 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: tumbled 12477.3% in 2021, then soared 836.31% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $3.8 million in 2021, then skyrocketed by 89.79% to $7.3 million in 2022, then plummeted by 424.4% to -$23.7 million in 2023, then soared by 113.96% to $3.3 million in 2024, then crashed by 302.36% to -$6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$6.7 million in Q4 2025, $17.7 million in Q3 2025, and -$47.9 million in Q2 2025.